• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma.

作者信息

Link Jason M, Liudahl Shannon M, Betts Courtney B, Sivagnanam Shamilene, Leis Kenna R, McDonnell Mary, Pelz Carl R, Johnson Brett, Hamman Kelly J, Keith Dove, Sampson Jone E, Morgan Terry K, Lopez Charles D, Coussens Lisa M, Sears Rosalie C

机构信息

Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR.

Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR.

出版信息

JCO Precis Oncol. 2021 Feb 5;5. doi: 10.1200/PO.20.00287. eCollection 2021.

DOI:10.1200/PO.20.00287
PMID:34036232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140804/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/086824c5bc4a/po-5-po.20.00287-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/dcb4dcca7c61/po-5-po.20.00287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/82b5704f8a25/po-5-po.20.00287-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/7a990cd1453b/po-5-po.20.00287-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/3e4ab254b18f/po-5-po.20.00287-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/7d97677c7dc4/po-5-po.20.00287-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/086824c5bc4a/po-5-po.20.00287-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/dcb4dcca7c61/po-5-po.20.00287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/82b5704f8a25/po-5-po.20.00287-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/7a990cd1453b/po-5-po.20.00287-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/3e4ab254b18f/po-5-po.20.00287-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/7d97677c7dc4/po-5-po.20.00287-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/930c/8140804/086824c5bc4a/po-5-po.20.00287-g007.jpg

相似文献

1
Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma.肿瘤浸润白细胞表型可区分胰腺腺癌相关患者的预后。
JCO Precis Oncol. 2021 Feb 5;5. doi: 10.1200/PO.20.00287. eCollection 2021.
2
Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma.影响早期胰腺腺癌患者治疗实施及治疗结果的因素。
Pancreas. 2011 Apr;40(3):480-2. doi: 10.1097/MPA.0b013e318205eab0.
3
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.胰腺浸润性腺癌和壶腹周围癌中MTAP基因的纯合缺失：一个潜在的新治疗靶点。
Cancer Biol Ther. 2005 Jan;4(1):83-6. doi: 10.4161/cbt.4.1.1380. Epub 2005 Jan 15.
4
An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.胰腺腺癌的遗传学、病理学及治疗介绍。
Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13. doi: 10.4161/cbt.307.
5
Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy.抗病毒状态将胰腺腺癌的两种分子表型分隔开：对腺病毒基因治疗的潜在相关性。
J Transl Med. 2010 Jan 29;8:10. doi: 10.1186/1479-5876-8-10.
6
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.通过K-ras基因直接测序检测胰腺腺癌伴孤立性肝转移中的多个肝微转移：一例报告
Surgery. 1999 Jan;125(1):113-6.
7
Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic?可切除边缘的胰腺腺癌，转化治疗现实吗？
Acta Oncol. 2014 Sep;53(9):1268-71. doi: 10.3109/0284186X.2014.887856. Epub 2014 Apr 16.
8
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.细胞组蛋白修饰模式可预测可切除胰腺腺癌的预后和治疗反应：来自 RTOG 9704 的结果。
J Clin Oncol. 2010 Mar 10;28(8):1358-65. doi: 10.1200/JCO.2009.24.5639. Epub 2010 Feb 8.
9
MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.微小 RNA-132 在胰腺导管腺癌中发挥独立的预后作用，并作为一种肿瘤抑制因子。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033818824314. doi: 10.1177/1533033818824314.
10
Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.胰腺癌的最新进展：新的预后生物标志物和靶向治疗——文献综述。
Biomolecules. 2021 Oct 6;11(10):1469. doi: 10.3390/biom11101469.

引用本文的文献

1
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer.持续的复制应激耐受性和克隆性T细胞反应可区分胰腺癌肝转移和肺转移的复发情况及预后。
Nat Cancer. 2025 Jan;6(1):123-144. doi: 10.1038/s43018-024-00881-3. Epub 2025 Jan 9.
2
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.产后乳腺癌具有独特的分子特征，预示着不良预后。
Nat Commun. 2021 Nov 3;12(1):6341. doi: 10.1038/s41467-021-26505-3.

本文引用的文献

1
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.转录异质性和胰腺导管腺癌鳞状特征的统一范式。
Nat Cancer. 2020 Jan;1(1):59-74. doi: 10.1038/s43018-019-0010-1. Epub 2020 Jan 13.
2
Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation.胰腺癌细胞的鳞状转化促进了基质炎症。
Elife. 2020 Apr 24;9:e53381. doi: 10.7554/eLife.53381.
3
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.
胰腺癌的转录表型是由肿瘤进化过程中的基因组事件驱动的。
Nat Genet. 2020 Feb;52(2):231-240. doi: 10.1038/s41588-019-0566-9. Epub 2020 Jan 13.
4
Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer.肿瘤纯度独立分型（PurIST）：一种用于胰腺癌肿瘤分型的临床稳健的单样本分类器。
Clin Cancer Res. 2020 Jan 1;26(1):82-92. doi: 10.1158/1078-0432.CCR-19-1467. Epub 2019 Nov 21.
5
Neutrophil Heterogeneity in Cancer: From Biology to Therapies.中性粒细胞异质性在癌症中的作用：从生物学到治疗策略。
Front Immunol. 2019 Sep 20;10:2155. doi: 10.3389/fimmu.2019.02155. eCollection 2019.
6
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.胰腺癌新型代谢亚型的综合分析促进了新的预后生物标志物的发现。
Front Oncol. 2019 Feb 27;9:115. doi: 10.3389/fonc.2019.00115. eCollection 2019.
7
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.胰腺导管腺癌的免疫表型：转录亚型的荟萃分析。
Int J Cancer. 2019 Aug 15;145(4):1125-1137. doi: 10.1002/ijc.32186. Epub 2019 Mar 18.
8
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.胰腺癌中基因组和转录组特征的整合揭示了转移中细胞周期进程的增加。
Cancer Cell. 2019 Feb 11;35(2):267-282.e7. doi: 10.1016/j.ccell.2018.12.010. Epub 2019 Jan 24.
9
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
10
Implementing a comprehensive translational oncology platform: from molecular testing to actionability.实施全面的肿瘤转化医学平台：从分子检测到可操作性。
J Transl Med. 2018 Dec 14;16(1):358. doi: 10.1186/s12967-018-1733-y.